. 2016 Sep 20;72(1):115–127. doi: 10.1093/jac/dkw381

Table 2.

AMP-resistant S. aureus display increased resistance to clinically prescribed antibiotics

Strain no.	Cycled with	Peptidoglycan synthesis inhibitors/clinical breakpoint^a (mg/L)			Detergent-like peptide antibiotics/clinical breakpoint^a (mg/L)		Protein synthesis inhibitors/clinical breakpoint^a (mg/L)								Folate synthesis inhibitors/clinical breakpoint^a (mg/L)	RNA synthesis inhibitor/clinical breakpoint^a (mg/L)
		VAN	TEC	CFT	DAP	PMB	GEN	CHL	CLI	ERY	LZD	TGC	TET	DOX	SXT	RIF
		R >2	R > 2	R > 1	R > 1	ND	R > 1	R > 8	R > 0.5	R > 2	R > 4	R > 0.5	R > 2	R > 2	R > 4	R > 0.5
		MIC (mg/L)^b
DA28823	WT	1.5	0.5	0.25	0.094	96	0.125	4	0.094	0.19	2	0.094	0.094	0.19	0.094	0.012
DA30560	no peptide	1.5	0.5	0.25	0.094	64	0.125	4	0.094	0.19	2	0.094	0.094	0.19	0.094	0.012
DA29677	LL-37	2	1.5	0.19	0.75	96	0.094	6	0.047	0.19	1.5	0.094	0.19	0.125	0.047	0.008
DA29680	LL-37	2	2	0.25	0.19	96	0.094	4	0.094	0.19	1.5	0.19	0.25	0.094	0.064	0.012
DA30557	WGH	2	1	0.38	0.19	192	1	4	0.064	0.125	2	0.094	0.25	0.094	0.064	0.012
DA30559	WGH	1.5	1.5	0.38	0.19	192	0.38	4	0.064	0.125	1	0.094	0.19	0.125	0.094	0.016
DA36424	LL-37 and WGH	2	1.5	0.38	0.38	96	0.19	4	0.125	0.25	2	0.19	0.25	0.25	0.094	0.012
DA35920	PR-39	2	2	0.19	1	128	0.25	3	0.094	0.38	1	0.125	0.125	0.094	0.094	0.016
DA37296	PR-39	2	1.5	0.25	0.38	384	0.5	6	0.125	0.38	2	0.125	0.19	0.125	0.064	0.008

VAN, vancomycin; TEC, teicoplanin; CFT, ceftaroline; DAP, daptomycin; PMB, polymyxin B; GEN, gentamicin; CHL, chloramphenicol; CLI, clindamycin; ERY, erythromycin; LZD, linezolid; TET, tetracycline; TGC, tigecycline; DOX, doxycycline; SXT, trimethoprim/sulfamethoxazole; RIF, rifampicin.

Light grey, 2–5-fold MIC increase; dark grey, >5-fold MIC increase.

^aDerived from EUCAST Clinical Breakpoint Table v. 5.0, valid from 1 January 2015 for Staphylococcus spp. (R, resistant; ND, no value determined).